
|Videos|December 30, 2022
2022 recap: Dr. Chi highlights milestones in stone disease
Author(s)Urology Times staff
“We've got a lot of movement in terms of understanding how stones form, some pharmaceutical interventions that we can use to prevent stones, and then how we can get even less invasive to try to get stones in the least morbid way for our patients,” says Thomas Chi, MD.
Advertisement
Urology Times® is wrapping up the year by diving into some milestones from different urologic specialties. In this interview, Thomas Chi, MD, recaps some of the clinical and research highlights in stone disease from the past year. Chi is a professor and associate chair at the University of California, San Francisco.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
BOND-003 Cohort C: Efficacy Results
5












